This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through ...

D Molecular Therapeutics (NASDAQ:FDMT) executives said the company is seeing strong clinical trial momentum for its lead retinal gene therapy candidate, 4D-150, as it advances through late-stage devel ...

An expert MD reveals clear insights into cataract surgery, spotlighting the breakthroughs in treatment: "We live in a time of miracle and wonder." The post “What I Wish I’d Known About Cataract ...

(Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...

RA tirzepatide for type 2 diabetes mellitus (T2DM) therapy has lower odds of instigating retinal complications.

The urgency is clear. Africa records roughly 1.2 million new cancer cases annually and more than 700,000 cancer-related deaths, with incidence expected to rise sharply. Diabetes and its complications ...

Aims To evaluate whether predominantly peripheral lesions (PPLs) and other imaging biomarkers on ultra-widefield (UWF) ...

Pipeline Advancing as Planned, Leading with OCS-01 Key Milestone Completion of LPLV in Both DIAMOND Phase 3 Trials; Data Readout on Track for June 2026Licaminlimab PREDICT-1 Trial in Active Site ...

An investigational oral therapy for diabetic macular edema (DME) did not significantly affect retinal thickening in a placebo ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory ...

ALLUVIUM showed vamikibart Q8W/Q4W improved DME outcomes but underperformed ranibizumab for BCVA (+4.6 to +7.1 vs +13 letters ...

Patients with proliferative diabetic retinopathy (PDR) had more success in preserving visual acuity when taking brolucizumab ...